PATENT CLAIM ANALYSIS

Application Number: 16020773
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-04
Patent Classification: ["424", "046000"]

Abstract:
Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchioalveolar lavage followed by assaying residual lung material.

Claim (Index 46):
The pharmaceutical composition according to  claim 40 , wherein the composition comprises particles having a MMAD of less than 5 microns.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 94.0
- Lexical Diversity: 2.25862
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12710167', '14248245', '11015196', '12822935', '10808044']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.789324604620484
- 35 USC 102 Novelty (BERT): 0.5491724537329324
- Combined Prediction Score: 0.7653093895317289
- Mean Citation Score: 365.409304
- Max Citation Score: 478.04288
- Similarity Product: 254.57802072875967

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test